You are here:Home-Chemical Inhibitors & Agonists-Wnt/Notch/Hedgehog-Porcupine-RXC004
RXC004

Chemical Structure : RXC004

CAS No.: 1900754-56-4

RXC004 (RXC-004, RXC 004)

Catalog No.: PC-20176Not For Human Use, Lab Use Only.

RXC004 (RXC-004) is a potent, selective Porcupine (PRCN) inhibitor, inhibits functional Wnt production from mouse L-Wnt3a cells with IC50 of 64 pM in luciferase reporters assays.

Packing Price Stock Quantity
25 mg Get quote
100 mg Get quote
250 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

RXC004 (RXC-004) is a potent, selective Porcupine (PRCN) inhibitor, inhibits functional Wnt production from mouse L-Wnt3a cells with IC50 of 64 pM in luciferase reporters assays.
RXC004 had no effect on downstream Wnt signaling.
RXC004 inhibited palmitoylation of Wnt, RXC004 also inhibited Wnt5a secretion from L-Wnt5a cells and reduced levels of β-catenin in L-Wnt3a cells.
Porcupine inhibition by RXC004 downregulated mRNA expression of Wnt pathway targets Axin2, RNF43, c-Myc, CD44, and MMP7 in cell lines with RNF43 LoF mutations and RSPO3 fusions.
RXC004 inhibited proliferation of cell lines with RNF43 mutations and RSPO3 fusions in a concentration-dependent manner but had no effect on cell lines with mutations in downstream Wnt signaling.
RXC004 reduced the proportion of cells in S-phase, and strongly inhibited expression of the mitosis marker phospho-histone-H3 in cells with upstream aberrations in Wnt pathway components.
RXC004 treatment (5 mg/kg once daily) inhibited tumor growth in SNU-1411/NOD-SCID xenografts, with inhibition of c-Myc gene expression in tumor.

Physicochemical Properties

M.Wt 439.40
Formula C21H16F3N7O
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

2-(5-methyl-4-(2-(trifluoromethyl)pyridin-4-yl)-1H-imidazol-1-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide

References

1. Phillips C, et al. Cancer Res Commun. 2022 Sep 2;2(9):914-928.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: